Ophtesia (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride, the active ingredient in Ophtesia, is a local anesthetic presented as a ophthalmic solution for topical eye use. It provides rapid surface anesthesia for diagnostic and minor therapeutic procedures on the ocular surface.

GNH USA supplies Ophtesia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ophtesia is a topical ocular anesthetic used in procedures that involve the surface of the eye. It is employed in the following clinical situations: - Corneal abrasion assessment: facilitates painless examination of the cornea. - Intra‑ocular pressure measurement: enables comfortable tonometry. - Minor ocular surgery: provides short‑lasting anesthesia for procedures such as foreign‑body removal. - Diagnostic fluorescein staining: reduces discomfort during dye application. - Phototherapeutic keratectomy (PTK) preparation: aids in patient comfort during pre‑treatment assessment.

Adverse reactions to Ophtesia are generally mild and transient, but clinicians should be aware of both common and rare events.

Common Side Effects: - Burning sensation: mild, transient irritation at the application site. - Stinging or itching. - Redness of the eye. - Tearing (epiphora). - Blurred vision: temporary loss of visual clarity. - Conjunctival hyperemia.

Serious or Rare Side Effects: - Allergic contact dermatitis: localized swelling and rash. - Corneal epithelial toxicity: persistent epithelial defects. - Persistent corneal haze. - Severe ocular inflammation. - Vision loss: rare but reported in cases of overdose or misuse. - Anaphylaxis: extremely rare systemic reaction.

When using Ophtesia, health professionals should consider several safety measures to minimise risk. - Patient history: review for known hypersensitivity to ester‑type anesthetics. - Application frequency: limit to the minimum number of doses required for the procedure. - Contact lens wearers: advise removal of lenses before administration. - Pediatric use: exercise caution and adjust technique for children. - Concomitant ocular drugs: assess potential additive irritation. - Store at room temperature: keep in the original container, protect from light and moisture.

Oxybuprocaine hydrochloride may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid): - Combined use with other topical anesthetics: risk of cumulative toxicity. - Concurrent administration with cytotoxic ophthalmic chemotherapy agents: may increase corneal toxicity.

Moderate Interactions (Monitor Closely): - Use with preservative‑containing eye drops: potential for increased irritation. - Co‑administration with anti‑inflammatory eye drops: monitor for additive effects on corneal healing. - Interaction with systemic antihistamines: may modestly prolong anesthetic effect. - Use with ocular lubricants containing benzalkonium chloride: watch for enhanced epithelial disruption.